Benzinga | Oct 7, 2020 10:15AM EDT

Alkermes Posts Briefing Docs For FDA AdCom Meeting On ALKS 3831

Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the Oct. 9, 2020 joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to review the company's New Drug Application (NDA) for ALKS 3831 (olanzapine/samidorphan). ALKS 3831 is an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder.

The joint advisory committee meeting, which is being held virtually, is scheduled to begin at 10:00 a.m. ET on Friday, Oct. 9, 2020. Both Alkermes and the FDA have prepared pre-recorded presentations, which will be viewed by the joint advisory committee prior to the meeting and will not be replayed during the meeting. The briefing materials, including the pre-recorded presentation slides and transcripts, are now posted to the FDA website and can be accessed here: https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-time-agenda-and-meeting-materials-october-9-2020-joint-meeting-psychopharmacologic-drugs.

The FDA has also established a docket for public comment on this meeting. The docket number is FDA-2020-N-1767 and can be accessed here: https://beta.regulations.gov/document/FDA-2020-N-1767-0001/comment.

The Prescription Drug User Fee Act (PDUFA) target action date for the ALKS 3831 NDA is Nov. 15, 2020.